Blinatumomab, a bispecific T‐cell engager (BiTE) immunotherapy targeting CD19 on B‐cells and CD3 on T‐cells, has revolutionized the treatment of pediatric B‐ALL. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.